替罗非班联合抗血小板药物治疗进展性脑梗死的效果研究

Effect of Tirofiban Combined with Antiplatelet Agents in Treatment of Progressive Cerebral Infarction

目的:探讨替罗非班联合抗血小板药物治疗进展性脑梗死(PCI)的效果。方法:选取2019年1月-2020年12月安徽省阜阳市界首市人民医院收治的80例PCI患者作为研究对象,按随机数字表分为两组,各40例。对照组应用抗血小板药物治疗,观察组在对照组基础上加用替罗非班治疗。比较两组治疗效果。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前,两组美国国立卫生院卒中量表(NIHSS)、红细胞凝集指数、日常生活能力评定量表(ADL)评分比较,差异无统计学意义(P>0.05);治疗后,观察组NIHSS评分、红细胞凝集指数低于对照组,ADL评分高于对照组,差异有统计学意义(P<0.05)。两组并发症发生率比较,差异无统计学意义(P>0.05)。观察组预后理想率高于对照组,差异有统计学意义(P<0.05)。结论:替罗非班联合抗血小板药物在PCI治疗中效果确切,值得推广。

Objective: To explore the effect of tirofiban combined with antiplatelet agents in treatment of progressive cerebral infarction. Methods: A total of 80 patients with progressive cerebral infarction in the Jieshou People’s Hospital in Fuyang City from January 2019 to December 2020 were selected as the study subjects, and they were divided into two groups according to the random number table, with 40 cases in each group. The control group was treated with antiplatelet drugs, and the observation group was additionally treated with tirofiban on the basis of the control group. The treatment effects of the two groups were compared.Results: The total effective rate of treatment in the observation group was higher than that in the control group, and the difference was statistically significant(P<0.05). Before treatment, there was no significant difference in the scores of National Institutes of Health Stroke Scale(NIHSS), erythrocyte agglutination index and activity of daily living(ADL) score between the two groups(P>0.05);after treatment, the NIHSS score and erythrocyte agglutination index of the observation group were lower than those of the control group, ADL score was higher than that of the control group, and the difference was statistically significant(P<0.05). There was no significant difference in the incidence of complications between the two groups(P>0.05). The rate of satisfactory prognosis in the observation group was higher than that in the control group, and the difference was statistically significant(P<0.05).Conclusion: Tirofiban combined with antiplatelet drugs has definite effect in the treatment of progressive cerebral infarction and is worthy of promotion.